
Aytu BioScience AYTU
$ 2.55
-0.78%
Quarterly report 2025-Q4
added 02-03-2026
Aytu BioScience P/S Ratio 2011-2026 | AYTU
Annual P/S Ratio Aytu BioScience
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.237 | 0.242 | 0.0973 | 0.00289 | 0.255 | 2.24 | 1.7 | 1.02 | 1.71 | 5.69 | 20.7 | 17.9 | 535 | 1.87 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.87 K | 0.00289 | 176 |
P/S Ratio of other stocks in the Biotechnology industry
| Issuer | P/S Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.75 | - | 2.43 % | $ 254 M | ||
|
Nanobiotix S.A.
NBTX
|
98.9 K | $ 30.34 | -0.82 % | $ 286 B | ||
|
I-Mab
IMAB
|
94.1 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.53 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
1.96 K | - | 2.54 % | $ 160 B | ||
|
Applied Therapeutics
APLT
|
54.1 | - | - | $ 8.42 M | ||
|
BioNTech SE
BNTX
|
35.7 | $ 95.5 | 3.83 % | $ 27.2 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.39 K | - | -1.52 % | $ 24.7 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
759 | $ 2.92 | -0.34 % | $ 6.35 B | ||
|
Midatech Pharma plc
MTP
|
137 | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.73 | $ 20.37 | -2.4 % | $ 952 M | ||
|
Acorda Therapeutics
ACOR
|
0.142 | - | -24.86 % | $ 820 K | ||
|
Институт стволовых клеток человека
ISKJ
|
2.61 | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
76.4 | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
144 | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
7.87 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
0.099 | - | -10.17 % | $ 12.2 K | ||
|
Celldex Therapeutics
CLDX
|
1.32 K | $ 32.24 | -4.1 % | $ 2.14 B | ||
|
Aeglea BioTherapeutics
AGLE
|
489 | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
1.42 | $ 1.4 | -0.71 % | $ 360 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
65.5 | - | - | $ 26.5 M | ||
|
Aptinyx
APTX
|
204 | - | -39.0 % | $ 4.57 M | ||
|
Aquestive Therapeutics
AQST
|
10.5 | $ 4.08 | -2.16 % | $ 436 M | ||
|
Aravive
ARAV
|
6.61 | - | -13.39 % | $ 1.45 M | ||
|
Arcutis Biotherapeutics
ARQT
|
9.15 | $ 24.21 | -1.47 % | $ 3.08 B | ||
|
AIkido Pharma
AIKI
|
0.935 | - | 1.93 % | $ 17.4 M | ||
|
Autolus Therapeutics plc
AUTL
|
4.27 | $ 1.49 | 1.36 % | $ 397 M | ||
|
Cidara Therapeutics
CDTX
|
116 | - | - | $ 1.41 B | ||
|
Ayala Pharmaceuticals
AYLA
|
11.2 | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
2.17 | - | - | $ 96.9 B | ||
|
Immutep Limited
IMMP
|
492 | $ 0.31 | -2.52 % | $ 1.08 B | ||
|
CureVac N.V.
CVAC
|
281 | - | - | $ 867 M | ||
|
BeiGene, Ltd.
BGNE
|
66.4 | - | 0.49 % | $ 251 B | ||
|
Evogene Ltd.
EVGN
|
71.3 | $ 0.81 | -1.16 % | $ 27.9 M | ||
|
Baudax Bio
BXRX
|
0.614 | - | 0.59 % | $ 63 K | ||
|
Alpine Immune Sciences
ALPN
|
8.94 | - | - | $ 2.17 B | ||
|
Cabaletta Bio
CABA
|
50.3 M | $ 3.13 | -1.26 % | $ 315 M |